Harm reduction-based and peer-supported hepatitis C treatment for people who inject drugs in Georgia

Harm reduction-based and peer-supported hepatitis C treatment for people who inject drugs in Georgia International Journal of Drug Policy 52 (2018) 16–19 Contents lists available at ScienceDirect International Journal of Drug Policy journal homepage: www.elsevier.com/locat e/drugpo Short Report Harm reduction-based and peer-supported hepatitis C treatment for people who inject drugs in Georgia a b b c Tamar Kikvidze , Niklas Luhmann , Elisabeth Avril , Maia Butsashvili , d b b a Konstantine Labartkava , Aurélie Etienne , Diane Le Pluart , Ina Inaridze , c a b, Ana Gamezardashvili , David Kharshiladze , Julie Bouscaillou Médecins du Monde Georgia, 46 Gutnis Street, Tbilisi, 0103, Georgia Médecins du Monde France, 62 rue Marcadet, 75018, Paris, France Clinic Neolab, 47 Tashkenti Street, Tbilisi, 0160, Georgia New Vector, 9 Mtskheta Street, Tbilisi, 0179, Georgia Background Sciences. The initial phase (2015–2016) of the NHCEP focused on providing 7000 free courses of Sofosbuvir (with Ribavirin+/ Eliminating hepatitis C PegInterferon) limited to persons with advanced liver fibrosis (F3 or more corresponding to elastometry above 10 kPa or FIB4 > 3.25). The introduction of new highly effective direct-acting antiviral The ongoing second phase(2016–2020) intends totreateveryperson (DAA) therapies has created an opportunity for the global chronically infected with HCV (Gvinjilia et al., 2016). To succeed in elimination of hepatitis C http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png International Journal of Drug Policy Elsevier

Loading next page...
 
/lp/elsevier/harm-reduction-based-and-peer-supported-hepatitis-c-treatment-for-8GLESjOB1L
Publisher
Elsevier
Copyright
Copyright © 2017 Elsevier B.V.
ISSN
0955-3959
D.O.I.
10.1016/j.drugpo.2017.11.014
Publisher site
See Article on Publisher Site

Abstract

International Journal of Drug Policy 52 (2018) 16–19 Contents lists available at ScienceDirect International Journal of Drug Policy journal homepage: www.elsevier.com/locat e/drugpo Short Report Harm reduction-based and peer-supported hepatitis C treatment for people who inject drugs in Georgia a b b c Tamar Kikvidze , Niklas Luhmann , Elisabeth Avril , Maia Butsashvili , d b b a Konstantine Labartkava , Aurélie Etienne , Diane Le Pluart , Ina Inaridze , c a b, Ana Gamezardashvili , David Kharshiladze , Julie Bouscaillou Médecins du Monde Georgia, 46 Gutnis Street, Tbilisi, 0103, Georgia Médecins du Monde France, 62 rue Marcadet, 75018, Paris, France Clinic Neolab, 47 Tashkenti Street, Tbilisi, 0160, Georgia New Vector, 9 Mtskheta Street, Tbilisi, 0179, Georgia Background Sciences. The initial phase (2015–2016) of the NHCEP focused on providing 7000 free courses of Sofosbuvir (with Ribavirin+/ Eliminating hepatitis C PegInterferon) limited to persons with advanced liver fibrosis (F3 or more corresponding to elastometry above 10 kPa or FIB4 > 3.25). The introduction of new highly effective direct-acting antiviral The ongoing second phase(2016–2020) intends totreateveryperson (DAA) therapies has created an opportunity for the global chronically infected with HCV (Gvinjilia et al., 2016). To succeed in elimination of hepatitis C

Journal

International Journal of Drug PolicyElsevier

Published: Feb 1, 2018

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches

$49/month

Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.

$588

$360/year

billed annually
Start Free Trial

14-day Free Trial